Skip to main content

Table 1 Characteristics of the study population of the VERROU-REA study (N = 396)

From: Trisodium citrate 4% versus heparin as a catheter lock for non-tunneled hemodialysis catheters in critically ill patients: a multicenter, randomized clinical trial

Characteristics Citrate (N = 199) Heparin (N = 197)
Age, years, mean (± SD) 69.4 (± 13.4) 69.5 (± 12.9)
Male gender, n (%) 127 (64%) 123 (62%)
BMI, mean (± SD) 30 (± 8.7) 29.8 (± 8.6)
Main reason for ICU admission, n (%)     
 Neurologic 9 (5%) 6 (3%)
 Cardiac 22 (11%) 30 (15%)
 Renal 44 (22%) 29 (15%)
 Respiratory 46 (23%) 41 (21%)
 Sepsis or septic shock 63 (32%) 65 (34%)
 Other shock 6 (3%) 11 (6%)
 Other reasons 9 (5%) 14 (7%)
Charlson comorbidities score, mean (± SD) 6.1 (± 3.4) 5.9 (± 2.7)
SAPS II at ICU admission, mean (± SD) 62.5 (± 17.3) 63.0 (± 18.6)
SOFA at randomization, mean (± SD) 10.3 (± 3.6) 10.4 (± 3.5)
First catheter insertion site, n (%)     
 Left internal jugular 16 (8%) 23 (12%)
 Right internal jugular 61 (31%) 64 (32%)
 Left femoral 43 (21%) 44 (22%)
 Right femoral 79 (40%) 66 (34%)
Type of RRT for the first non-tunneled catheter, n (%)     
 Both continuous and intermittent 36 (18%) 39 (20%)
 Intermittent only 83 (42%) 82 (42%)
 Continuous only 76 (38%) 67 (34%)
 RRT not initiateda 4 (2%) 9 (5%)
Systemic anticoagulation, n (%) 119 (68%) 117 (66%)
Systemic antimicrobials for the first non-tunneled hemodialysis catheter, n (%) 160 (81%) 168 (85%)
  1. SD, standard deviation; BMI, body mass index (kg/m2); ICU, intensive care unit; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment; Q1, Q3, first and third quartiles; RRT, renal replacement therapy; LMWH, low molecular weight heparin
  2. aReasons are detailed in the Additional file 1